Akebia Therapeutics, Inc. - Common Stock (AKBA)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 24, 2026Investment Snapshot
- P/B of 11.50 — trading above book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -40.3%
- Revenue growing at 47% annually
Akebia Therapeutics, Inc. - Common Stock (AKBA) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $375 million . Key value metrics: P/B ratio 11.50, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Akebia Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, AKBA shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -40.3% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.48.
StockPik's composite Value Score for AKBA is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AKBA reports a high gross margin of 81.0% (sector average: 33.5%) and a modest operating margin of 9.0%.
AKBA shows revenue growing at 47% year-over-year, with earnings growing at 92%.